Last reviewed · How we verify
guideline-based treatment for DM
Guideline-based treatment for diabetes mellitus applies standardized clinical protocols to optimize glycemic control and reduce complications through evidence-based therapeutic strategies.
Guideline-based treatment for diabetes mellitus applies standardized clinical protocols to optimize glycemic control and reduce complications through evidence-based therapeutic strategies. Used for Type 2 diabetes mellitus, Type 1 diabetes mellitus.
At a glance
| Generic name | guideline-based treatment for DM |
|---|---|
| Sponsor | General Hospital of Shenyang Military Region |
| Modality | Small molecule |
| Therapeutic area | Endocrinology / Diabetes |
| Phase | FDA-approved |
Mechanism of action
This represents a treatment approach rather than a single drug entity, implementing established clinical guidelines for diabetes management. It typically involves a combination of lifestyle modifications, oral antidiabetic agents (such as metformin, sulfonylureas, DPP-4 inhibitors, or SGLT2 inhibitors), and/or insulin therapy, selected and sequenced according to current medical guidelines to achieve target blood glucose levels and prevent microvascular and macrovascular complications.
Approved indications
- Type 2 diabetes mellitus
- Type 1 diabetes mellitus
Common side effects
- Hypoglycemia
- Weight gain
- Gastrointestinal disturbances
- Lactic acidosis (metformin-related)
Key clinical trials
- Project MiNT: Assessing the Impact of Food & Video-Based Nutrition Education on Patients With Poorly Controlled Diabetes (NA)
- Fingolimod for Type 2 Diabetes Mellitus (PHASE4)
- Electronic Alerts for Heart Failure Prevention in Diabetes (NA)
- Addressing Gaps in the Hypertension and Diabetes Care Continuum in Rural Bangladesh: The Dinajpur Study (PHASE1)
- The Influence of Advanced Age, Obesity and Diabetes Type on Course and Outcome of Pregnancy With Diabetes Mellitus.
- Evaluation of an Integrated Microfinance and Depression Care Program for Women (NA)
- Diabetes in India Nutrition Guidelines Study (DINGS) (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: